Valuation: Wockhardt Limited

Market Cap 310B 3.25B 2.82B 2.64B 2.41B 4.53B 4.61B 30.94B 12.12B 155B 12.21B 11.95B 518B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 326B 3.42B 2.96B 2.77B 2.53B 4.76B 4.84B 32.49B 12.73B 163B 12.83B 12.55B 544B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-1.13%
1 week-5.60%
Current month-2.57%
1 month+5.45%
3 months+17.46%
6 months+36.18%
Current year+32.03%
1 week 1,900.1
Extreme 1900.1
2,056.9
1 month 1,792.4
Extreme 1792.4
2,067.7
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-5.60%+30.51%+652.47% 3.29B
-0.12%-1.12%+20.74%+71.50% 48.92B
-3.54%+2.63%+53.92%+118.76% 41.53B
-0.32%+0.21%-2.78%+17.02% 12.43B
+6.43%+5.40%+24.64%+82.96% 11.7B
-0.19%-0.38%+30.98%+136.36% 9.09B
+1.95%+9.12%+25.38%+40.22% 7.4B
-1.26%+3.80%+38.66%-13.94% 7.15B
+1.10%+2.29%+11.06%+184.02% 6.66B
-1.22%+4.46%-25.04%+29.64% 5.95B
Average +0.17%+3,563.42%+20.81%+131.90% 15.41B
Weighted average by Cap. -0.53%+4,959.49%+27.76%+94.72%

Financials

2025 2026
Net sales 30.35B 318M 276M 258M 236M 443M 451M 3.03B 1.19B 15.19B 1.19B 1.17B 50.68B 34.62B 363M 315M 294M 269M 506M 514M 3.45B 1.35B 17.33B 1.36B 1.33B 57.81B
Net income -470M -4.93M -4.27M -4M -3.65M -6.86M -6.98M -46.88M -18.37M -235M -18.5M -18.1M -785M 2.13B 22.33M 19.35M 18.12M 16.53M 31.11M 31.63M 212M 83.23M 1.07B 83.85M 82.02M 3.56B
Net Debt 14.33B 150M 130M 122M 111M 209M 213M 1.43B 560M 7.17B 564M 552M 23.93B 15.53B 163M 141M 132M 121M 227M 231M 1.55B 607M 7.77B 611M 598M 25.93B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-08-11 ₹1,909.40 -1.13% 1,073,711
26-08-10 ₹1,931.20 -4.44% 1,702,030
26-08-07 ₹2,021.00 +2.33% 547,985
26-08-06 ₹1,975.00 -1.55% 578,202
26-08-05 ₹2,006.10 -0.82% 863,920
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock